Like some of the other companies that are behind in the immuno-oncology space, Novartis AG is relying on combination treatments to get it back in the game and is hoping that its strength in gene therapies will give it an advantage. The Swiss pharma knows it can't recover in the near-term, but is planning to be on top in five years.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.